Skip to Main Content

Contribute Try STAT+ Today

generic drugs

Most Read

Pharmalot By Ed Silverman

Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned

First Opinion By Chenery Lowe, Liesl Broadbridge and Laynie Dratch

What genetic counselors can teach the CDC about communicating uncertainty

UCLA Hospital ICU virtuous cycle

First Opinion By Cynda Hylton Rushton, Ian Wolfe and Tener Goodwin Veenema

It’s staff, not stuff: Applying crisis standards of care to allocating health care workers

Health Tech By Mohana Ravindranath

For doctors drowning in emails, one health system’s new strategy: pay for replies

Michel Vounatsos

The Pharmalot View By Ed Silverman

If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Biotech’s red tape, the latest billionaire science project, & a (possible) Omicron reprieve

In the Lab By Angus Chen

New research casts doubt on how combination cancer therapies work in tandem

In the Lab By Andrew Joseph

Kisses, licks, and drool: Study shows how ‘saliva sharing’ shapes babies’ understanding of the closest relationships

All Coverage

Pills and Money

First Opinion By Farasat A.S. Bokhari

Clinton’s proposed ban on pay-for-delay deals would do little to lower drug prices

Pharmalot By Ed Silverman

Feds probe drug maker for prices of generic dermatology meds

advertisement

Pharmalot By Ed Silverman

Drug maker loses appeal of antitrust pay-to-delay case in Europe

EpiPen

Pharmalot By Ed Silverman

How Mylan tried to keep Teva from selling a generic EpiPen

EpiPen

Business By Stephanie Simon

Mylan to launch generic version of EpiPen, at half the cost

FDA Campus

Pharmalot By Ed Silverman

Drug makers continue to abuse citizen petitions, FDA tells Congress

Pharmalot By Ed Silverman

State Department accused of interfering with efforts for affordable medicines

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: FDA overlooks troubles at Chinese supplier to avoid shortages

AstraZeneca signage

Pharmalot By Ed Silverman

AstraZeneca loses court battle to prevent generic versions of Crestor

Pharmalot By Ed Silverman

Teva, one of the biggest generic makers, joins the brand-name club

Injectable drugs

Pharmalot By Ed Silverman

FDA narrowly defines the ability of compounders to make approved medicines

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Was the FDA commissioner paid by drug makers last year?

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Endo may sell assets as reliance on price hikes wanes

Pharmalot By Ed Silverman

India makes it easier to buy its generic drug makers, but will anyone bite?

FDA Securities Fraud

Pharmalot By Ed Silverman

Former FDA official charged with securities fraud for tipping off hedge fund

Turing Pharma

Pharmalot By Ed Silverman

Lawmakers look to prevent drug makers from thwarting generic competition

Pharmalot By Ed Silverman

India’s new patent policy spurs debate over implications for pharma

FDA

Pharmalot By Ed Silverman

FDA again delays rule to allow generic drug makers to change labels

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Walmart and McKesson team up to buy generic drugs

Pharmalot By Ed Silverman

What generics? Americans spent an extra $73b for brand-name meds

Generic medication

The Pharmalot View By Ed Silverman

Generic drug labels don’t always list known side effects. It’s time to change that

Glaxo Smith Kline

Pharmalot By Ed Silverman

Glaxo, other drug makers appeal UK fines for pay-to-delay deals

FDA Headquarters

Pharmalot By Ed Silverman

FDA warns another Indian drug maker on serious quality control lapses

Pharmalot By Ed Silverman

Two drug makers complain India is thwarting licenses for selling generics

FDA Campus

Pharmalot By Ed Silverman

FDA proposes biosimilar labeling that favors generic drug makers